Please login to the form below

Not currently logged in
Email:
Password:

David Epstein joins Flagship Pioneering as executive partner

He most recently served as CEO of Novartis Pharmaceuticals

Flagship Pioneering David EpsteinUS-based Flagship Pioneering has appointed former Novartis Pharmaceuticals chief executive David Epstein as its executive partner.

In this newly-created position, Epstein will begin working with Rubius Therapeutics, a red blood cell-focused exploratory venture within the Flagship portfolio, as chairman of its board.

He brings over 25 years of drug development, commercialisation and leadership experience within the pharmaceuticals industry, most recently as chief executive officer of Novartis Pharmaceuticals.

Prior to taking up this lead role in 2010, Epstein founded Novartis Oncology and Novartis Molecular Diagnostics in 1989, leading the start-up businesses as president and chief executive officer.

Dr Noubar Afeyan, founder and chief executive of Flagship, said: “David is a leader and long-time pioneer within the pharma industry, having developed dozens of new medicines benefiting millions of patients around the world.

“His progressive approach to science and business acumen gleaned over his tenured career in the pharmaceutical industry complements Flagship's culture and team.

“We will apply his expertise broadly as we continue making and realising the maximum potential of disruptive innovations that yield unprecedented therapies.”

25th January 2017

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics